More power for more patients than ever before across all stages of hypertension

Powerful BP Efficacy Demonstrated for the Hypertensive Patients You Treat

For Your Goals...
Prompt and Powerful BP Efficacy

Both AVAPRO and AVALIDE provide prompt BP lowering at
2 weeks^13-15
AVALIDE: INCLUSIVE trial demonstrated powerful BP reduction in patients with systolic blood pressure (SBP) uncontrolled on monotherapy¹⁶
AVAPRO: Powerful SBP and diastolic blood pressure (DBP) reductions comparable to one of the most widely prescribed antihypertensive agents, amlodipine, at starting doses¹⁵

In clinical trials with hypertensive patients:
AVAPRO/AVALIDE^‡ provided tolerability similar to placebo at every dose

AVAPRO: no significant difference from placebo in the incidence of cough (2.8% vs placebo 2.7%), fatigue (4.0% vs placebo 3.0%), and edema (2.0% vs placebo 3.0%)
AVAPRO: not associated with an increased incidence of dry cough, as is associated with ACE inhibitor use

^‡AVAPRO Studies I–VII; AVALIDE Studies I–IV.

AVALIDE: Tolerability/safety profile comparable to monotherapy in the moderate and severe hypertension studies

Available in a full range of dosage strengths

Tablets shown are not actual size.

Read more about dosing for AVAPRO and AVALIDE.

WARNING: USE IN PREGNANCY When pregnancy is detected, discontinue AVAPRO or AVALIDE as soon as possible. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. [See Warnings and Precautions: Fetal/Neonatal Morbidity and Mortality in the full Prescribing Information.]

Please see Indications, Important Safety Information and full Prescribing Information.

Next page: Prompt and Powerful BP Lowering at 2 Weeks